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1. Introduction
It is well believed that human embryonic stem cells (hESCs [1]) and induced pluripotent stem
cells (hiPSCs [2]) are of great potential use for tissue substitutes (for example, blood cells) and
to cure various congenital disorders. In mammals, hematopoiesis has already been precisely
described in murine system but not yet in human. Early development of hematopoietic system
can be well defined by a series of waves from primitive hematopoiesis (early embryogenesis)
to definitive ones (late fetal stages). In vitro induction of undifferentiated hESC to functionally
mature blood cells may mimic the early hematopoietic development during human embryonic
and fetal stages. It also provides an ideal model to uncover molecular and cellular mechanisms
controlling early development of human hematopoiesis. On the other hand, functionally
matured blood cells derived from hESC/hiPSCs are expected to be widely used for clinical
cellular therapies. Although almost all kinds of the mature blood cells can be generated from
hESCs, there still lacks solid evidence for the generation of reconstituting hematopoietic stem
cells (HSCs) from hESC or hiPSC. So far until now, in vitro hESC-derived blood cells possess
phenotypical maturity and partial functions while still more or less share embryonic/fetal
characteristics, differing greatly from their adult counterparts. This indicated that in vitro
culture systems are not perfect enough to exert full mature activities. Lack of knowledge about
the molecular and cellular regulations in human early hematopoiesis has handicapped the
development of research on hESC/hiPSC-derived hematopoiesis.
Having been focusing on basic and clinical research on hESC/hiPSC-derived functionally
mature blood cells for long, our group has established an efficient method to induce large-scale
production of multipotential hematopoietic progenitor cells by coculturing hESC/hiPSCs with
murine hematopoietic niche-derived stromal cells [3-6]. By this method, large quantity of
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matured erythrocytes and other functional blood cells could be harvested. In this chapter we
will discuss the latest progress in this research field along with our recent discoveries. We will
emphasize on the origin, evolution and the development of both primitive and definitive
hematopoietic waves, especially those derived from hESCs in vitro systems. The critical
problems need to be solved and the research prospects of this field will also be addressed at
the end of the chapter.
2. The primitive and definitive waves of hematopoiesis in mammals
2.1. Anatomical sites of hematopoiesis at different developmental stages
Hematopoiesis takes place in some discrete anatomical niches that change temporally and
spatially in mammals. Its maturation along with developing ontogeny is a successive event
initiated from yolk sac (YS) and then to intra-embryonic sites. The classical opinion believes
that para-aortic splanchnopleura (P-Sp)/aorta-gonad-mesonephros (AGM) ought to be the sole
location for the emergence of intra-embryonic hematopoiesis, where the earliest HSCs exist.
During midgestation, these HSCs move to fetal liver (FL), a predominant hematopoietic place
until birth [7, 8]. Hematopoietic precursors seed the bone marrow (BM) in late gestation, where
maintaining the principal site of HSC activity lifelong. However, a recent discovery provided
solid proof that before HSCs enter the circulation, the embryonic day (E) 10.5–11.5 mouse head
is an unappreciated site for HSC emergence within the developing embryo independent to the
AGM region [9].
Yolk Sac. The first wave of blood cell generation begins at embryonic day E7.0 at YS and is
termed primitive hematopoiesis, producing large erythroblasts that express embryonic
hemoglobins [10, 11]. The second wave, termed definitive hematopoiesis, produces smaller
erythroblasts that express adult hemoglobins and various other blood cells [12]. Long-term
repopulating HSCs (LTR-HSC) appear only in the second wave [13].
The murine YS is a bilayer organ composed of extra-embryonic mesoderm cells apposing to
visceral endoderm cells. Its mesoderm layer produces the first blood cells within blood islands
[14, 15]. Between E8.0 and E9.0, the outer layer’s cells of the blood island in YS differentiate
into endothelial cells and form a spindle shape while the vast majority of the inner cells
gradually lose their intercellular attachments along with their differentiation into primitive
erythroblasts [16].
The research of Yoder’s group support that the YS not only acts as the sole site of primitive
erythropoiesis but also possibly serves as the first source of definitive hematopoietic progen‐
itors during embryonic development [15,17]. The result of BFU-E assay indicated that follow‐
ing the early wave of primitive erythropoiesis, definitive erythroid progenitors appear at 1-7
somite pairs (E8.25) and solely exist within the YS. After that the definitive erythroid (according
to the CFU-E assay), mast cell and bipotential granulocyte/macrophage progenitors develop
in the YS [18]. Another proof comes from Ncx1-/- embryo, which could not initiate a heartbeat
on embryonic day E8.25 while development continued through E10. There is similar amount
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of primitive erythroid progenitors and definitive HPCs in YS of Ncx1-/- and WT mice through
E9.5, while the P-Sp region in Ncx1-/- mice lacks primitive erythroblasts and definitive
hematopoietic progenitor cells (HPCs) from E8.25 to E9.5 [17]. So it is reasonable to believe
that primitive erythroblasts and nearly all definitive HPCs seeded the fetal liver after E9.5 are
generated from the YS between E7.0-E9.5 and are re-distributed into the embryo proper via
the systemic circulation [17]. The definitive hematopoiesis may originate from primitive
hematopoiesis during embryonic development and migrating HSCs come from the murine
YS, which seed the liver and initiate hematopoiesis on 10.0 day postcoitus (dpc). But whether
YS cells isolated before day 11.0 dpc possess any long-term repopulating HSC activity remains
controversy. Yoder et al proved that donor day 9.0 dpc YS cells could establish long-term
hematopoietic system in conditioned newborns, but not in adult recipients [19]. When these
early YS cells were co-cultured for 4 days with AGM-S3, an AGM region-derived stromal cell
line, they obtained such capacity of reconstitution [20]. All the evidence so far agree that YS
itself couldn’t provide long-term repopulating HSC activity while the hematopoietic cells
originate from YS could own this activity through proper “education” by definitive hemato‐
poiesis niches or the stromal cell line derived from them [20, 21].
AGM. Following the onset of circulation at E8.5, hematopoietic progenitors rapidly move
within the embryo. Determining the anatomical origins of definitive hematopoiesis is a
complicated and controversial topic. It is now widely recognized that main source of definitive
hematopoiesis originates from the AGM region [8]. Using irradiated adult mice as the
recipients, Müller et al reported that LTR-HSC first appeared in the AGM region at 10 dpc and
expanded in 11 dpc AGM region [13]. Medvinsky et al then demonstrated that, at day 10 in
gestation, hematopoietic stem cells initiate autonomously and exclusively within the AGM
region under in vitro organ culture condition [8]. All these findings suggested that the AGM
region at 10 to 11 dpc provides a microenvironment suitable for generation of LTR-HSC. Xu
et al obtained a stromal cell line derived from the AGM region of 10.5 dpc mouse embryo
(AGM-S3) that could support the growth and proliferation of hematopoietic progenitor/stem
cells from adult mouse bone marrow and human cord blood without additional cytokines [21].
The same research group found that no definitive hematopoiesis-derived colony-forming cells
were generated from YS and P-Sp cells at 8.5 dpc before co-cultured with AGM-S3 cells.
However after 4-day co-culture of 8.5 dpc YS and P-Sp cells with AGM-S3, spleen colony-
forming cells and HSCs capable of reconstituting definitive hematopoiesis in adult mice
simultaneously appeared [20]. It is proposed that precursors that had the potential to generate
definitive HSCs appear in both extra-embryonic (YS) and intra-embryonic (P-Sp) region, the
latter providing microenvironment to support the definitive hematopoiesis from both
precursors.
Fetal liver and bone marrow. At 9 dpc, the liver rudiment begins to form an evagination of
gut into the septum transversum. The liver does not generate hematopoietic cells de novo but
is instead colonized at late E9 by hematopoietic cells generated in other tissues [22; 23]. The
first erythroblasts are visible in the liver at 9 dpc. From 10 dpc onwards, the erythroid lineage
begins to develop definitive characteristics. Myeloid CFU-Cs appears in the fetal liver at 9 dpc
and macrophages and B cells are present at 10-11 dpc [24]. Although most of these differenti‐
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ated cell types are found early in liver development, the more immature cell types, such as the
CFU-S progenitor and the LTR-HSC [7, 25], can be detected only beginning at 11 dpc. Since
the liver rudiment is colonized by exogenous blood cells [26]HSCs must arise elsewhere.
Previous study on mouse embryo supported that HSCs able to engraft adult mice were present
in the liver beginning at E11–E12 [27-29]. These fetal liver–derived HSCs expressed CD34, c-
kit, AA4.1, and Sca-1 surface markers, and were thought to migrate to the fetal BM after E15
[30], the latter providing a continuous supply of mature blood cells for the lifespan (Figure 1).
Figure 1. Primitive and definitive hematopoiesis
2.2. Characterization of the progenies derived from primitive and definitive hematopoiesis
The embryonic and fetal erythrocytes only come from primitive hematopoiesis wave while
definitive HSCs and T lymphocytes only come from definitive hematopoiesis wave [31]. We
will summarize the cellular and molecular characteristics of these cells in primitive and/or
definitive hematopoiesis.
2.2.1. Erythrocytes
The erythroid cells within the blood islands of YS are known as primitive or embryonic
erythrocytes, specially named as EryP. Differing from the ones found in the FL and adult BM,
these YS primitive erythrocytes are typically large in size, nucleated and express embryonic
pattren of hemoglobins [32, 33]. The development of primitive erythroid lineage is so transient
that its progenitors reach top number in the developing YS at E8.25 and soon become unde‐
tectable at E9.0. They would never occur in the late stage of embryonic development [18, 33].
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Following the early wave of primitive erythropoiesis and before the generation of adult-
repopulating HSCs, a transient erythromyeloid wave of definitive hematopoietic progenitors
(erythroid/myeloid progenitors [EMPs]) emerges in the YS. This YS-derived definitive wave
begins E8.25 and colonizes the liver by E10.5. All maturation stage of erythroid precursors and
the first definitive erythrocytes could be observed in the liver and circulation at E11.5 [34].
Initially, the development and differentiation of both primitive and definitive erythroid
precursor cells depend on growth factor signaling [35],while the later committed erythroid
progenitor is different [18, 36].
After HSC expansion in the fetal liver between E12.5 and E16.5, the definitive erythroid
progenitors are exponentially increased, which produce massive number of definitive
erythroid precursors exclusively expressing adult globins [37, 38]. Thus, HSCs that colonize
the fetal liver are commonly described as the origin of “definitive” hematopoiesis in the
mammalian embryo.
2.2.2. Macrophage
Another mature hematopoietic cells present in the early YS are macrophages. Progenitor
cells of functional macrophages were first found in YS of the mouse between day 7 and 8
of gestation. Pro-monocytes and macrophages were firstly identified in the 10-day YS and
11-day  FL,  indicating  that  the  primitive  macrophage  progenitors  are  “proximal”  to  the
promonocyte on the pathway of sequential macrophage maturation [39]. The observation
that they mature rapidly, bypassing the monocyte stage of development, and express lower
level of certain genes than later stage macrophages suggests that they could represent a
unique population [40, 41].
However, the distinction of primitive macrophages is not as clear as the primitive erythroid
lineage, since it is unknown if the molecular events leading to their development differ
significantly from other types of macrophages. Because that is a close relationship between
microphages and the maturation of erythroid cells, the special developmental trait of micro‐
phages probably is the adaptation for the primitive erythrogenesis process [12, 18]
2.2.3. Mast cells
In fetal stages, a large number of MC precursors could be found in murine YS and fetal blood,
indicating a strong wave of MC development taking place in early embryo [42, 43]. But little
is known about human MC development during the embryonic and fetal stages. The human
and non-human primates MCs could be generated from ES cells when co-cultured with mouse
AGM or OP9 (a fetal bone cell line from M-CSF knockout mouse) cells [4, 44], providing
important information about human MC development in early embryonic stage.
In humans, two types of MCs have been identified based on their neutral protease composi‐
tions [45]. Connective tissue-type MCs (CT-MCs)mainly located in skin and sub-mucosal area
and express tryptase, chymase, MC carboxypeptidase, and cathepsin G in their secretory
granules. Mucosal-type MCs (M-MCs) that locates in alveolar wall and small intestinal mucosa
express only tryptase. The non-human primate ESC-derived MCs are similar to CT-MC in
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phenotype and functionally identical to human skin counterparts, indicating that a different
pathway may occur in early development for this two type of MCs. [4].
2.2.4. Lymphocytes
It is ambiguous to obtain common opinion about the origin site and time of lymphocytes
during embryonic development. Some researchers persist that lymphoid precursors could
be detected in the YS (extraembryo) prior to the embryo,  which is  as early as Day 8 of
gestation [46,  47].  The opposite  opinion believe that  lymphoid precursors  appear  in  the
embryo proper before the YS [48]. Other researchers believe that they appear in both sites
at the same developmental stage [49, 50]. The clonal assays of Godin et al. suggested that
this  controversy  might  be  due  to  difference  in  the  experimental  condition among these
groups to favor lymphoid potential but not lymphoid commitment [51]. If the latter as a
standard, the early fetal liver was the first place to produce committed lymphoid precur‐
sors [52]. Different to myelopoiesis, lymphogenesis has no primitive wave and is specifical‐
ly derived from definitive hematopoiesis.
2.2.5. LTR-HSC
The definitive hematopoiesis is defined by LT-HSCs that could reconstitute the hematopoiet‐
ic system in irradiated adult mouse. The primitive hematopoiesis could not support such
a reconstitution in adult mouse but only in fetal ones [8]. The primitive hematopoiesis has
too simple and incomplete hematopoietic hierarchy compared with definitive hematopoie‐
sis  and could not  be  detected of  the  complete  activity  of  LT-HSC [24].  The mechanism
controlling  developmental  difference  between  two  waves  of  hematopoiesis  has  been
obviously observed, but whether “primitive” HSC exists is still a controversial topic [53].
Some researches support the opinion that LT-HSC also originates from YS. Only after the
“education” on AGM, these YS LT-HSC progenitors become the functional LT-HSCs, for
the hematopoietic  cell  isolated from E9.5  YS could reconstitute  hematopoietic  system in
irradiated adult mouse after 4 days co-cultured with mAGM-S3 cells [20]. Immediately after
primitive hematopoiesis at YS, the definitive hematopoietic progenitors could be detected
by generating CFU-GM and BFU-E, indicating that HSCs probably originate from YS and
finally mature at AGM region [18]. But other groups persist that LT-HSC has no relation
to YS and was produced de novo from AGM [54].
2.3. Molecular mechanisms controlling the transition from primitive to definitive
hematopoiesis
Recently, findings from different gene targeting experiments have demonstrated that the
primitive and definitive hematopoietic lineages develop from a common precursor by distinct
molecular programs, and that the respective cell populations are regulated by different growth
factors. Though the controversy still exists about their origins, the YS-derived cell population
that only have primitive hematopoiesis potential could obtain definitive hematopoiesis
potential by the “education” on mAGM cells in vitro [20]. The YS cell grafted to fetal liver or
fetal marrow could also obtain LT-HSC activity [19, 55]. This provides strong evidences to
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support that the primitive hematopoietic progenitor cells could transfer to definitive ones in
the microenvironment of fetus definitive hematopoiesis origin, such as mouse AGM, fetal liver
and fetal marrow. It is obvious that molecular signals released by definitive hematopoiesis
niche cells play a key role in such “education”.
Because the component of hemoglobin provides clear trace to describe the developmental
stages of red blood or its precursor that distinguish the primitive from definitive hemato‐
poiesis, the erythropoiesis serves as an ideal model to research both waves of hematopoie‐
sis.  It  also provides clue to dissect  their  molecular switch mechanism, which is  also the
main object in our discussion about the molecular regulation of both primitive and definitive
hematopoiesis.
In situ studies of the early embryo have demonstrated that genes known to play a role in
the onset of hematopoietic development (e. g., GATA-2,scl/tal-1, rbtn2) are expressed prior
to the appearance of the blood islands [56]. This suggests that the molecular program that
leads to hematopoietic commitment begins shortly after gastrulation at approximate Day
7.0  of  gestation.  Under  the  control  of  tal-1,  rbtn2,  GATA-2,  and  GATA-1  that  was  ex‐
pressed  orderly,  primitive  mammalian  erythropoiesis  takes  place  in  a  subpopulation  of
extra-embryonic mesoderm cells during gastrulation. Though these transcriptional factors
were also expressed in other region of embryo in the same stage (tal-1 and rbtn2 also in
posterior  embryonic  mesoderm  and  GATA-1  and  GATA-2  expression  also  in  extra-
embryonic  tissues  of  ectodermal  origin),  their  expression  pattern  in  extra-embryonic
mesoderm  cells  still  play  a  key  role  in  understanding  the  molecular  mechanism  of
hematopoietic commitments [56].
By gene-targeting studies on transcription factors essential for development of all hemato‐
poietic lineages, the key control genes for primitive and/or definitive hematopoiesis (such as
Gata1, Gata2, AML1, C-myb, EKLF, rbtn2) were well analyzed.
GATA gene family. GATA1 expression is highly restricted in erythroid cells, megakaryocytic
cells, eosinophils, dendritic cells, and MCs of hematopoietic cell [57]. It is essential for red blood
cell (RBC) development because GATA-1-/- mice will die between E10.5–E11.5 in mid-
gestation by anemia [58]. In such mutated embryo, only primitive erythroid cells could be
found in the peripheral blood, which are arrested at a proerythroblast stage and express βH1,
α and ζ-globin transcripts, then die by apoptosis [59]. Matured definitive erythroid cells were
completely absent in GATA-1-/- mice [60-62]. GATA-2, another important member of GATA
family, was expressed in many other multi-lineage progenitors and HSCs [63] and also plays
important role in proliferation, survival and differentiation of early hematopoietic cells,
though the result of its functional mutation is relatively mild compared with GATA-1 [59].
At the late stage of erythrocyte development the “GATA switch” is the key molecular mech‐
anism for erythroid differentiation companied by down-regulating GATA2 and up-regulating
GATA1 expression. This is the process that GATA-1 occupies the GATA binding site on the
upstream element of GATA2 gene and represses the expression of the latter [64]. In general,
after terminal erythroid differentiation start, GATA1 directly opens the expression of erythroid
lineage-affiliated genes such as β-globin, Alas2, and Gata1 itself while at the same time
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represses Gata2, c-Kit, c-Myb, and c-Myc, responding for the proliferation of progenitors in
earlier stages of hematopoiesis [65].
AML1/Runx1. Homozygous mutations of AML1/Runx1 did not interfere normal morpho‐
genesis and YS-derived erythropoiesis, but completely inhibit FL hematopoiesis, leading to
the death of embryo around E12.5. The same mutation in ES cells do not influence their
differentiation potential into primitive erythroid cells in vitro while stop occurence of any
definitive myeloid or erythroid progenitors in both the YS and FL after injected to blastocysts
to produce chimeric animals. Above proofs support the key role of AML1 and AML1-regulated
target genes to all lineages in definitive hematopoiesis [10, 66]
c-Myb. c-Myb is highly expressed in immature hematopoietic cells and its expression is down-
regulated as they become more differentiated [67, 68]. c-Myb controls self-renewal and
differentiation of adult HSCs and its disruption seriously depletes the HSC pool and inhibits
the definitive hematopoiesis [69].
EKLF. EKLF is zero or very weakly expressed in hematopoietic stem cells and multipoten‐
tial myeloid progenitors, while arise since more matured stages and play a role all the time
later for RBC differentiation. Its expression is up-regulated when myoloid and erythriod
progenitors were committed to the erythroid lineage while down-regulated when differen‐
tiate  toward  megakaryopoiesis  [70].  During  the  global  expansion  of  erythroid  gene
expression  in  primitive  and definitive  lineages,  EKLF also  plays  a  direct  role  in  globin
switching. EKLF is weakly expressed during embryonic and fetal development, which led
to a low expression of adult β-globin, Bcl11a and a high one of γ-globin. While in adults,
EKLF is highly expressed in definitive RBCs that results in high levels of adult β-globin
and Bcl11a expression, and represses γ-globin expression [71]. Finally, EKLF stop the cell
cycle of RBCs at the terminal maturation [72]. EKLF/KLF1 mutations will change the RBC
phenotypes or even lead to disease. [73, 74]
Rbtn2. Rbtn2 is a nuclear protein expressed in erythroid lineage in vivo, which is essential for
erythroid development in mice. The homozygous mutation of rbtn2 inhibits YS erythropoiesis
and leads to embryonic lethality around E10.5. YS tissue from homozygous mutant mice and
double-mutant ES cells could not process erythroid development in in vitro differentiation
system, showing a key role for Rbtn2 in erythroid differentiation, which is high related to
GATA-1 [75]
EPO/EPOR. Erythropoietin is a glycoprotein produced primarily by kidney and is the
principal factor to regulate RBC production, mainly functioning on erythroid progenitors
within the FL and adult BM [76]. The erythroid progenitors before BFU-E stage and RBC after
late basophilic erythroblast stage are not responsive to EPO. Proliferation in CFU-E stage could
highly responsive to EPO and this response is very transient. The affinity between erythro‐
poietin and its receptor (EPO-R) and their concentration decide strength of such response
during the erythropoiesis. EPO-R signaling pathway is necessary for both primitive and
definitive erythropoiesis [77, 78].
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3. hESC-derived primitive and definitive hematopoietic cells
The first hESC line was established by Thomson’s group in 1998 [1] and then the first hiPSC
line by Yamanaka’s group in 2007 [2]. Both cells provide possibility to uncover various normal
or diseased mechanisms in early human development. By in vitro differentiation system,
factors controlling the primitive and definitive hematopoiesis could be investigated in detail
using the method of embryoid body (EB) forming [79], or co-culture with hematopoietic niche-
derived stromal cell lines [3-6, 80, 81]. Among them, method of EBs could obtain large quantity
of blood cells that were not well matured, mimicking the primitive hematopoietic cells [82,
83]. Then, co-culture with OP9 cells was applied to promote the differentiation based on EB
method and large-scale production of mature erythrocytes with some definitive properties
could be obtained [84, 85]. Although OP9 co-culture system could obtain robust growth of
matured blood cells, it is clearly not a natural process and could not be used as proper model
to elucidate the natural mechanism controlling early human hematopoiesis. The stromal cells
isolated from early hematopoietic niches, such as AGM region, FL and late-stage fetal BM,
should be more reasonable candidates to support the in vitro differentiation of hESC/hiPSC-
derived hematopoietic stem/progenitor cells. The Lako’s group compared the differences
among several in vitro differentiation systems based on stromal cell co-culture and optimized
their culture conditions. Their result suggested that AGM-derived cell line was most proper
for the hematopoiesis differentiation of ESC. [86]
Based on in vitro differentiation systems, researchers tried to make clear the details of early
human hematopoiesis using hESCs as a model. Keller’s group found two distinct types of
hemangioblasts during hESCs differentiation culture, one could give rise to primitive eryth‐
roid, macrophages and endothelial cells, while the other one generated only primitive
erythroid and endothelial cells [87]. Their work provided the first evidence to prove the
existence of hemangioblasts derived from hESCs in vitro. The follow-up work showed that
under the control of growth factors and hematopoietic cytokines the hematopoiesis and
myelopoiesis will happen during the later stage; and common bi-potent progenitor capable of
generating erythroid and megakaryocytic cells could be observed, mimicking the process in
vivo [88, 89]. Through the analysis of hemoglobin components, an erythroid maturation could
be observed by the ratio of β-globin expression during hESC differentiation culture, which
seems a maturation switch but not lineage switch [90]. Above researches indicated that the in
vitro hESC differentiation system could reflect the in vivo hematopoietic process during the
early human embryonic development.
Slukvin’s group applied PO9 co-culture system to explore the detail pathway from hESCs to
definitive hematopoiesis. They firstly characterized a population of differentiating hemato‐
poietic cells defined by the expression of CD43, which is distinct to endothelial and mesen‐
chymal cells. Then they defined the erythro-megakaryocytic progenitors
(CD34+CD43+CD235a+CD41a+/-CD45-) and multi-potent lymphohematopoietic progenitors
(CD34+CD43+CD235a-CD41a-CD45-) in later stage, which replicated the beginning of
definitive hematopoiesis in some degree [91, 92]. The human myelomonocytic cells could also
be generated from expansion and differentiation of pluripotent stem cell-derived lin-
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CD34+CD43+CD45+ progenitors. All the defined population above could be detected during
the in vitro differentiation for different hESCs or hiPSCs lines [92].
By different culture conditions, nearly all of the blood lineages could be obtained from hESCs
according to the experience from murine ESC protocols, which pave the way to the clinic
application [93]. Jame’s group also identified a wave of hemogenic endothelial development
during the transition from endothelial to hematopoietic cell [94], reflecting the classic property
of definitive hematopoiesis. Their result showed that the definitive hematopoiesis could be
researched in vitro differentiation system and most progenitor population could be obtained
in such a system.
Although research on the early development of human hematopoiesis using human embryo
is rigorously restricted by ethics, so far accumulated data have clearly demonstrated that in
vitro hESC-derived hematopoiesis is more or less similar to the events happening in murine
fetal development (Figure 2). Thus, research on hESC-hematopoiesis should contribute greatly
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Figure 2. Comparison of mouse model and in vitro hESC/hiPSC-derived hematopoiesis
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3.1. hESC-derived erythrocytes
Research on hESC-derived erythrocytes is one of the hot points because of the fact that
development of erythrocytes shows distinct trait between primitive and definitive waves.
More important is that the matured RBCs have no nucleus, which could avoid the exogenous
gene interference when clinically applied to treat patients. Much labor has been donated to
optimize the method of in vitro differentiation of RBCs from hESCs. For example, Lu’s group
firstly use EBs formation and then co-culture with OP9 to obtain a high yield of erythrocytes
with some efficiency of enucleation. However, these erythrocytes were still immature because
only 16% of these hESC-derived erythrocytes expressed β-globin [84]. Similar work has been
done by several other groups using OP9 system [95, 96]
In our laboratory, we have recently established efficient blood cell-yeilding systems by co-
culture of hESC/hiPSCs with murine AGM and FL stromal cells (Figure 3). In the co-culture,
undifferentiated hESC/hiPSC colonies grow up and differentiate firstly to a mesoderm-like
structure, then to hematopoietic progenitor cells on days 10 to 14. In the second suspension
culture, these hESC/hiPSC-derived hematopoietic progenitors are further induced to some
specific blood cell lineages, such as erythrocytes, mast cells, and eosinophils, etc. [3]. By a clone-
tracing method, we gained concrete results that hESC-derived erythrocytes kept continuously
progressing toward maturation over a time course. The expression of β-globin vs ε-globin
showed a typical switching pattern, mimicking the normal development of human erythro‐
cytes. On day 12 of the co-culture with murine FL-derived stromal cells, hESC-derived
erythrocytes (BFU-E) express β-globin at about 60%, but up-regulated to almost 100% with
additional 6 days of culture. These matured hESC-derived erythrocytes can undergo enuclea‐
tion and release oxygen [5].
Our results showed that the in vitro differentiation from hESCs to matured hematopoietic cells
is a progressive process if proper co-culture condition provided. Functionally matured blood
cells similar to those from the definitive hematopoiesis could be obtained in large-scale
production by this method.
3.2. hESC-derived HSCs
The most challenging task for research on hESC/hiPSC-derived hematopoiesis is to obtain the
real HSC from in vitro differentiation system [97]. Although hESC/hiPSC-derived hemato‐
poietic cells that could be engrafted in immune compromised mice have been reported [86,
98-102], effort to obtain real HSCs from hESCs has largely been done in vain during past years.
In most experiments, the engraftment rate was very low and mostly restricted to the myeloid
lineage, and it was ambiguous if these engrafed cells were derived from real HSCs. The co-
culture with S17 could induce hESCs to HSC-like properties with low capacity of RBC potential
[103]. If a modified cell line generated from mAGM (AM20.1B4) was used the RBC activity of
HSC will be increased much [86]. But these hESC-derived HSC-like cells could not repopulate
in NOD-SCID mice, representing they were not true definitive HSCs that satisfy the functional
definition.




A recent report showed that when co-cultured with OP9-DL1 cells, the hESC-derived hema‐
topoietic progenitor cells that formed endothelium-lined cell clumps could be induced into T-
lineage cells [104]. These hESC-derived T cells expressed sequential surface markers from T-
lymphoid progenitors (CD34+CD7+) to matured T cells (double positive CD4+CD8+and finally
maturedCD3+CD1-CD27+). The T-lineage cell production provided concrete evidence that
hESC-derived hematopoiesis endowed with definitive property. The functional matured
hESC-derived NK cells could also be generated by sequential co-culture on different feeder
cells [105, 106]. But the detail of HMC molecular and globulin class-switching during this
process has still not been elucidated.
3.4. Hemangioblasts
The blood islands region in YS consists of clusters of primitive erythroblasts surrounded by
mature endothelial cells. The close development relationship between hematopoietic and
endothelial cells in such a region indicated that these lineages ought to share a common
progenitor named as the hemangioblast [16, 33, 107]. This concept was provided nearly one
century ago [108,109] while it has been circumstantially supported by the latest molecular
genetic and embryological proofs [110-114]. More direct evidence came from the in vitro
Figure 3. Co-culture of hESC/hiPSCs with murine AGM or FL stromal cells
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differentiation system based on ESCs. Some differentiation models identified a progenitor with
properties of the hemangioblast [115, 116], indicating that the primitive hematopoiesis derived
from ESCs should pass through a hemangioblast stage. Further studies showed that these
hemangioblasts might have more potential than hematopoietic and endothelial cells, such as
smooth muscle [117, 118].
hESC-derived hemangioblasts have also been identified in differentiation cultures [87]. These
hESC-derived hemangioblasts were defined by the expression of KDR and could generate
clonal cells sharing both hematopoietic and vascular potential. There were two distinct types
of hESC-derived hemangioblasts: one gave rise to primitive erythroid cells, macrophages, and
endothelial cells and the other generated only the primitive erythroid population and endo‐
thelial cells. This finding provided evidence that hESC-derived hematopoiesis mimicked the
normal development pattern of human earliest stage of hematopoietic commitment.
3.5. Hemogenic endothelium
Different to hemangioblasts from YS, the concept of “hemogenic endothelial” come from the
research of AGM, which is in the ventral wall of the aorta and buds off HSCs [13]. The molecular
control of hemogenic endothelium is different to that of hemangioblasts. For example, Runx1
was indispensable for the hematopoiesis originated from hemogenic endothelia, but not
hemangioblasts [119, 120]. And the hemogenic endothelium did not originate from heman‐
gioblasts but presumptive mesoangioblasts, which could express endothelial-specific genes
and ultimately express HSC-associated markers [121]. Since hemogenic endothelium is closely
related to definitive hematopoiesis and has been regarded as the necessary stage for generation
of HSCs, the details of its potential and developmental process to produce HSCs should be
finely elucidated [122-125].
In some in vitro differentiation systems, hESC-derived CD34+ hemogenic progenitor cells
could also be detected with the endothelium potential [3, 126]. In an OP-9 co-culture system,
hESC-derived hemogenic endothelium progenitors (HEPs) were identified pinpoint by VE-
cadherin+CD73-CD235a/CD43- intermediate phenotype, which arise at the post primitive
streak stage of differentiation directly from a hematovascular mesodermal precursor (KDR
+APLNR+PDGFRalow/-). These HEPs differ from non-HEPs (VE-cadherin+CD73+) and early
hematopoietic cells (VEcadherin+CD235a+CD41a−) [124]. This subtle finding may provide clue
to facilitate generation of HSCs from hESCs (Figure 4).
3.6. Switching mechanisms controlling primitive hematopoiesis to definitive one
The origin of two waves of hematopoiesis was distinct in the sight of embryogenesis by the
research for Xenopus [127], mice [128] and human [54]. However, the reciprocal transplant test
in Xenopus embryo proved that the hematopoietic progenitor cell in VBI(corresponding to YS)
and DLP(corresponding to AGM) could change their potential according to microenvironment
of the graft site [129]. Similarly, blast-like cells derived from murine ESCs could differentiate
to both primitive and definitive lineages [130]. In our study by a clonal tracing method, hESC-
derived erythrocytes showed the primitive properties at the early stage and progressively
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turned to be definitive ones along with co-culture on FL cells [5], indicating that there exists a
possible switching mechanism controlling the conversion.
However, the molecular mechanism controlling such a switch remains unclear so far. The
switch observed in process of hESC-derived hematopoiesis probably is caused by the influence
or induction of the definitive hematopoietic niche-derived stromal cells (AGM, FL). The
cellular and molecular signals, including the growth factors and adhesion proteins expressed
by feeder cells and growth factors added in medium ought to play a key role to activate the
switch controlling the definitive hematopoiesis (such as Hedgehog, Notch1 and BMP signal
pathways). Among them, HoxB4 had been identified as the key factor to promote such a switch
[131]. Many key factors expressed in primitive and/or definitive erythrogenesis could also be
tracked in ESC-derived hematopoiesis [94, 132]. Since the hemoglobin switch of erythrocyte
could be used as the indicator of premitive and definitive hematopoiesis, the erythrogenesis-
related factors, such as GATA1, GATA2, AML1, SCL, EKLF, ought to be changed their
Figure 4. Development of hemangioblasts and hemogenic endothelia from pluripotent stem cells
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expression profile during such a switch. A thorough transcriptome analysis by deep sequenc‐
ing or gene chip should be useful tools to detect hESC-derived hematopoietic switch.
4. Concluding remarks and future perspectives
The in vitro production of functionally matured blood cells from hESC/hiPSCs has provided
an excellent model for both basic research and clinical applications. hESC/hiPSC-derived RBCs
are highly fancied because of their unlimited use as the substitute for blood transfusion, not
to mention the the utilization of hESC/hiPSC-derived HSCs in transplantation. On the other
hand, hiPSCs can provide patient-tailored models for analyzing the pathogenesis of malignant
blood diseases and thus develop individual treatment by molecular corrections. Innate
immune-related cells differentiated from hESC/hiPSCs will also help us to reveal the initial
establishment of human immune system, and to explore drug screening system and cell
therapy model for deficiencies of innate immunity.
However, before the successful application of hESC-derived cellular therapy, there are still
many problems needed to be solved. The molecular mechanisms controlling both primitive
and definitive hematopoiesis should be clarified at first. The HSC-like cells and functional
matured blood cells derived from hESC / hiPSC in vitro must also be proven their activities in
vivo. Besides, more efficient culture system free from xenobiotics must be optimized.
In order to realize above aims, the following efforts need to be done to promote the research
in this field:
1. The latest molecular biological technology and other new technique tool should be applied
in the future research.
Currently, Tetracycline (tc) and Tet repressor (TetR) system (tet-on and off) is one of the most
matured and widely applied regulatory systems [133] in organisms ranging from bacteria to
mammals. The technique by Transcription activator-like effector nucleases (TALENs [135,
136]) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) systems [136, 137] have also been developed. These methods let us be able to
do molecular manipulation in genomic scale(named “genome edit”) by unlimited times
against single cell line without obvious influence to the cell characteristic, thus provide an ideal
model to investigate the development events in hESC-derived hematopoiesis.
2. A highly efficient animal-source-free 3D culture system should be developed to search
for the generation of hESC-derived HSCs.
A big problem that hampers the progress in research on hESC-derived hematopoiesis is a lack
of a proper culture system that fully mimics the microenvironment of early development of
human hematopoiesis. An ideal culture model should be completely free of any animal source
substitutes and to great extent imitate a live structure as done in vivo circumstances. Since
HSCs develop in a complicated niche composed of various cell types (endothelial cells,
osteoblasts, mesenchymal cells, etc. ), a 3D culture model mixed by several hematopoietic niche
cells should benefit the efficiency of generating true HSCs from hESCs.
Human Embryonic Stem Cell-Derived Primitive and Definitive Hematopoiesis
http://dx.doi.org/10.5772/58628
101
3. The new concept and theory should be introduced to conduct the research of hESC-
derived hematopoiesis.
According to the recent researches by Deng and other group [138, 139], the pluripotency of
stem cells is only the balance between several transcription factor groups controlling layer
lineage differentiation. Their finding denied the existence of special pluripotent factors and
showed that maintenance of ESC/iPSCs may be only because that all the way to any differen‐
tiation direction has been blocked by mutually antagonistic lineage specifiers [140]. Such
concept may also help us to uncover the controlling balance by some specifiers in early
hematopoiesis, especially for those controlling primitive and definitive ones. Since we always
try to obtain more definitive blood cells for clinic application, to discover the key factor leading
to definitive hematopoiesis is a challenging task to do. Moreover, how to define and describe
the essence of HSCs at molecular level is also an issue need to be re-addressed.
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